Vertex One Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Vertex One Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-100,542	Closed	-$4.65M	–	105
2013 Q3	$4.65M	Buy	100,542 +5,000	+5%	+$219K	0.63%	46
2013 Q2	$4.27M	Buy	+95,542	New	+$4.15M	0.74%	35

Other funds holding BMY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vertex One Asset Management's BMY Position: Q4 2013 in Review

Vertex One Asset Management sold out of Bristol-Myers Squibb (BMY) in Q4 2013, closing a stake of 100,542 shares — an estimated $4.65M sold.

Vertex One Asset Management first reported a position in BMY in Q2 2013 and held it in 2 quarters. The position peaked at $4.65M in Q3 2013. 1,312 funds tracked by Wall St. Rank hold BMY as of Q4 2013.

Vertex One Asset Management reported no remaining Bristol-Myers Squibb position as of Q4 2013 after selling out during the quarter.
Vertex One Asset Management sold 100,542 Bristol-Myers Squibb shares in Q4 2013, an estimated $4.65M.
Vertex One Asset Management first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 2 quarters.
Vertex One Asset Management's Bristol-Myers Squibb position peaked at $4.65M in Q3 2013.
1,312 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2013.

Based on Vertex One Asset Management's 13F filing for Q4 2013, filed 14 Feb 2014.